U.K. Court Upholds NICE Guidance On Alzheimer’s Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Judge finds in favor of agency in five claims brought by Eisai but directs NICE to clarify advice for people with learning disabilities and whose first language is not English.
You may also be interested in...
NICE Finally Recommends Alzheimer's Therapies For Mild Disease
New clinical data lead U.K.'s cost regulator to recommend expanded reimbursement for Aricept, Exelon and Reminyl among patients with mild Alzheimer's disease, and for Exiba in moderate disease.
NICE Finally Recommends Alzheimer's Therapies For Mild Disease
New clinical data lead U.K.'s cost regulator to recommend expanded reimbursement for Aricept, Exelon and Reminyl among patients with mild Alzheimer's disease, and for Exiba in moderate disease.
Eisai Formally Requests Judicial Review Of NICE Alzheimer’s Appraisal
Grounds for review include procedural issues, irrationality and human rights, according to Eisai.